Bristol-myers Squibb Compnay

Other

Bristol Meyers Squibb Company

Syngene International Limited

Hao Zhang

Yan Shi

Peter Tai Wah Cheng

Jun Li

Shiwei Tao

Robert F Kaltenbach, Iii

Jun Shi

Sean Chen

James R Corte

Pratik Devasthale

Lawrence J Kennedy

Ying Wang

Peter T W Cheng

Sutjano Jusuf

Kumaravel Selvakumar

Ramesh Babu Reddigunta

Charles Z Ding

Jeffrey A Robl

Joseph Anthony Tino

Richard B Sulsky

Wei Meng

Peter T Cheng

Yoon T Jeon

Tianan Fang

Steven J Walker

Shung C Wu

Suresh Dhanusu

Timothy F Herpin

Xiang-Yang Ye

Wei Wang

Lidet A Negash

Scott A Bolton

Daniel Machlis

Nathaniel Boyless

Eva Lu

Ramesh Badu Reddigunta

Sriram Siva

Jiayi Liu

Iii Robert F Kaltenbach

Robert F Kaltenbach Iii

Robert F Iii Kaltenbach

Peter TW Cheng

Dennis E Ryono

Sean S Chen

The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Oxabicyclo acids as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Isoxazole carboxylic acids as LPA antagonists

Cyclopentyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

An x-axis curvable LED lighting system includes an elongated notched x-axis curved channel enclosed in a casing which can be freely bent without a machine having a bottom portion and one or more walls extending therefrom; an elongated lens to secure over a top of the elongated curved channel; and a flexible light strip, having a mounting strip to secure to one of the one or more walls of the elongated curved channel; LED lights attached to the mounting strip by an extension such that the LED lights are positioned within the elongated curved channel along the bottom portion; the LED lights emit light through the elongated lens.

X-axis curvable LED lighting system and method of use

The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

Systems and methods for image registration and self-localization for onsite and offsite viewing are provided. In one aspect, systems and methods for spherical image based registration and self-localization for onsite and offsite viewing, such as augmented reality viewing and virtual reality viewing, are provided. In one embodiment, a system includes a portable electric device fitted with a device camera, an external omnidirectional spherical camera, and a remote server. In one embodiment, a method of use employs a set of fiducial markers inserted in images collected by a spherical camera to perform image registration of spherical camera images and device camera images.

Spherical image based registration and self-localization for onsite and offsite viewing

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid pyrazole azoles as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azoles as LPA antagonists

The present invention provides compounds of Formula (Ia) or (Ib):Formula (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid isoxazole azoles as LPA antagonists

Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, X, X, and Xare each independently CRor N; provided that no more than two of X, X, X, or Xare N; L is Calkylene substituted with 0 to 4 R; Ris (&#x2014;CH)R; a is an integer of 0 or 1; Ris each independently halo, cyano, hydroxyl, amino, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; Ris hydrogen, Calkyl, Cdeuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; Ris Calkyl, Cdeuterated alkyl, Chaloalkyl, Calkenyl, Ccycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, &#x2014;(Calkylene)-(Ccycloalkyl), &#x2014;(Calkylene)-(6 to 10-membered aryl), &#x2014;(Calkylene)-(3 to 8-membered heterocyclyl), or &#x2014;(Calkylene)-(5 to 6-membered heteroaryl); wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R; or alternatively, Rand R, taken together with the N atom to which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R; Rand Rare each independently hydrogen, halo, cyano, hydroxyl, amino, Calkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Ris halo, oxo, cyano, hydroxyl, amino, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Rare each independently deuterium, halo, hydroxyl, amino, cyano, Calkyl, Cdeuterated alkyl, Calkenyl, Calkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl; or alternatively, two R, taken together with the atoms to which they are attached, form a 3 to 6-membered carbocyclic ring or a 3 to 6-membered heterocyclic ring each of which is independently substituted with 0 to 3 R; Ris selected from &#x2014;CN, &#x2014;C(O)OR, &#x2014;C(O)NRR, &#x2014;CO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;SO&#x2014;OH, &#x2014;SO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;P(O)(OH), tetrazol-5-yl, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, CH&#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CH&#x2014;SO&#x2014;OH, &#x2014;CH&#x2014;SO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CH&#x2014;P(O)(OH), tetrazol-5-ylmethylene; Ris Calkyl, Ccycloalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl; Ris hydrogen or Calkyl; and Rand Rare each independently hydrogen, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; and Ris halo, cyano, hydroxyl, amino, Calkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors. 

Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists

Growing community of inventors

Belle Mead, NJ, United States of America

Hao Zhang